Aerodynamic Particle Size Distribution (APSD)
Our range of precision engineered cascade impactors measure the size distribution (particle size) of inhaled drug products, providing critical information about where particles in aerosol clouds are likely to be deposited in the lungs following inhalation.
View More Details
Ancillaries
Optimise inhaler testing workflows with our broad range of supporting equipment required to make up fully-operating test systems for Delivered Dose Uniformity (DDU) and Aerodynamic Particle Size Distribution (APSD) of orally inhaled and nasal drug products (OINDPs).
View More Details
APSD Data Analysis Software
Inhalytix® – Efficiently converts raw APSD data into performance-defining metrics for all OINDPs
View More Details
Special Applications
Copley Scientific offers a range of testing equipment for additional qualification and validation of orally inhaled and nasal drug products (OINDPs), including assessments of generic drug formulations, inhaled dissolution testing and improving IVIVCs.
View More Details
Improving IVIVCs
Better IVIVC has long been an industry aim. This is particularly difficult in the case of inhaled and nasal products because of the complications involved in precisely correlating drug deposition behaviour with clinical efficacy, the impact of patient-to-patient variability and the complex interaction between formulation and device.
View More Details
Realistic Throat and Nasal Cavity Model
The drug mass sized by the cascade impactor (impactor sized mass) should ideally be representative of the dose that would actually enter the lungs. To achieve this, the induction port or other accessory used to interface the device to the impactor must capture a representative fraction of the dose. Our throat and nasal models have a standardised internal geometry more representative of in vivo physiology than a standard induction port and suitable for a range of patient profiles.
View More Details

Inhaler Development Testing Services

Latest Inhaler Testing News